Trial Profile

A Phase I Dose-Escalation Study of CPI-613 (Devimistat) in Combination With Chemoradiation in Patients With Pancreatic Adenocarcinoma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Devimistat (Primary) ; Gemcitabine (Primary)
Indications Adenocarcinoma; Pancreatic cancer; Pancreatic ductal carcinoma
Focus Adverse reactions

Most Recent Events

29 Jul 2024 Planned primary completion date changed from 1 Aug 2026 to 1 Aug 2025.
10 Apr 2024 As per results presented at the 115th Annual Meeting of the American Association for Cancer Research, as CPI-613 was not associated with any additional toxicities, specifically cytopenia(s), after the first two pts, the study protocol was amended to allow CPI-613 to be administered on weeks gemcitabine was held for cytopenia(s).
10 Apr 2024 Results for safety presented at the 115th Annual Meeting of the American Association for Cancer Research

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com